Telemetry Investments’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $484K | Buy |
32,250
+12,250
| +61% | +$112K | 0.76% | 32 |
|
|
2022
Q3 | $236K | Sell |
20,000
-3,000
| -13% | -$40.6K | 0.3% | 80 |
|
|
2022
Q2 | $260K | Buy |
23,000
+9,500
| +70% | +$191K | 0.31% | 89 |
|
|
2022
Q1 | $404K | Sell |
13,500
-5,500
| -29% | -$149K | 0.64% | 59 |
|
|
2021
Q4 | $504K | Buy |
19,000
+6,750
| +55% | +$204K | 0.65% | 52 |
|
|
2021
Q3 | $445K | Buy |
12,250
+4,250
| +53% | +$167K | 0.6% | 56 |
|
|
2021
Q2 | $347K | Sell |
8,000
-1,000
| -11% | -$37.8K | 0.48% | 69 |
|
|
2021
Q1 | $308K | Sell |
9,000
-1,601
| -15% | -$63.4K | 0.35% | 93 |
|
|
2020
Q4 | $371K | Sell |
10,601
-21,899
| -67% | -$634K | 0.63% | 59 |
|
|
2020
Q3 | $780K | Buy |
32,500
+9,950
| +44% | +$244K | 1.69% | 25 |
|
|
2020
Q2 | $413K | Hold |
22,550
| – | – | 1.12% | 38 |
|
|
2020
Q1 | $352K | Hold |
22,550
| – | – | 1.23% | 33 |
|
|
2019
Q4 | $483K | Sell |
22,550
-200
| -0.9% | -$4.12K | 1.61% | 21 |
|
|
2019
Q3 | $425K | Sell |
22,750
-650
| -3% | -$13.4K | 1.23% | 22 |
|
|
2019
Q2 | $611K | Sell |
23,400
-6,600
| -22% | -$149K | 0.47% | 36 |
|
|
2019
Q1 | $771K | Buy |
30,000
+4,000
| +15% | +$91.4K | 0.39% | 36 |
|
|
2018
Q4 | $598K | Buy |
26,000
+13,900
| +115% | +$392K | 0.38% | 65 |
|
|
2018
Q3 | $388K | Sell |
12,100
-5,900
| -33% | -$177K | 0.18% | 71 |
|
|
2018
Q2 | $509K | Buy |
18,000
+5,500
| +44% | +$196K | 0.19% | 58 |
|
|
2018
Q1 | $442K | Sell |
12,500
-11,490
| -48% | -$460K | 0.17% | 80 |
|
|
2017
Q4 | $931K | Buy |
23,990
+3,990
| +20% | +$152K | 0.35% | 51 |
|
|
2017
Q3 | $508K | Sell |
20,000
-2,000
| -9% | -$48.6K | 0.18% | 72 |
|
|
2017
Q2 | $601K | Buy |
22,000
+5,000
| +29% | +$137K | 0.28% | 63 |
|
|
2017
Q1 | $563K | Buy |
17,000
+1,831
| +12% | +$46.7K | 0.25% | 59 |
|
|
2016
Q4 | $361K | Buy |
15,169
+6,269
| +70% | +$180K | 0.2% | 63 |
|
|
2016
Q3 | $327K | Buy |
8,900
+400
| +5% | +$11.5K | 0.21% | 63 |
|
|
2016
Q2 | $190K | Sell |
8,500
-11,500
| -58% | -$286K | 0.1% | 97 |
|
|
2016
Q1 | $416K | Sell |
20,000
-5,000
| -20% | -$123K | 0.12% | 64 |
|
|
2015
Q4 | $758K | Hold |
25,000
| – | – | 0.26% | 60 |
|
|
2015
Q3 | $618K | Hold |
25,000
| – | – | 0.26% | 79 |
|
|
2015
Q2 | $802K | Buy |
25,000
+5,000
| +25% | +$191K | 0.36% | 60 |
|
|
2015
Q1 | $714K | Sell |
20,000
-10,000
| -33% | -$274K | 0.39% | 51 |
|
|
2014
Q4 | $681K | Buy |
+30,000
| New | +$607K | 0.42% | 63 |
|
Other funds holding RIGL
AC
Telemetry Investments's RIGL Position: Q4 2022 in Review
Telemetry Investments increased its Rigel Pharmaceuticals (RIGL) stake by 61% in Q4 2022, buying an estimated $112K and bringing the position to 32,250 shares worth $484K. The position accounts for 0.76% of the portfolio, ranked #32.
Telemetry Investments first reported a position in RIGL in Q4 2014 and has held it in 33 quarters since. The position peaked at $931K in Q4 2017. 119 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.
- Telemetry Investments held 32,250 shares of Rigel Pharmaceuticals worth $484K as of Q4 2022.
- Telemetry Investments bought 12,250 Rigel Pharmaceuticals shares in Q4 2022, an estimated $112K.
- Rigel Pharmaceuticals made up 0.76% of Telemetry Investments's portfolio in Q4 2022, its #32 holding.
- Telemetry Investments first reported a position in Rigel Pharmaceuticals in Q4 2014 and has held it in 33 quarters since.
- Telemetry Investments's Rigel Pharmaceuticals position peaked at $931K in Q4 2017.
- 119 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.
Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.